Reference
- Béraud, C., Dormoy, V., Danilin, S., Lindner, V., Béthry, A., Hochane, M., Coquard, C., Barthelmebs, M., Jacqmin, D., Lang, H., & Massfelder, T. (2015). Targeting FAK scaffold functions inhibits human renal cell carcinoma growth. International Journal of Cancer, 137(7), 1549–1559. https://doi.org/https://doi.org/10.1002/ijc.29522
- Cai, C., Wu, Q., Luo, Y., Ma, H., Shen, J., Zhang, Y., Yang, L., Chen, Y., Wen, Z., & Wang, Q. (2017). In silico prediction of ROCK II inhibitors by different classification approaches. Molecular Diversity, 21(4), 791–717. https://doi.org/https://doi.org/10.1007/s11030-017-9772-5
- Chen, I. H., Shih, H. C., Hsieh, P. W., Chang, F. R., Wu, Y. C., & Wu, C. C. (2015). HPW-RX40 restores anoikis sensitivity of human breast cancer cells by inhibiting integrin/FAK signaling. Toxicology and Applied Pharmacology, 289(2), 330–340. https://doi.org/https://doi.org/10.1016/j.taap.2015.09.011
- Fashena, S. J., & Thomas, S. M. (2000). Signalling by adhesion receptors. Nature Cell Biology, 2(12), E225–E229. https://doi.org/https://doi.org/10.1038/35046654
- Frame, M. C., Hitesh, P., Bryan, S., Daniel, L., & Eck, M. J. (2010). The FERM domain: Organizing the structure and function of FAK. Nature Reviews. Molecular Cell Biology, 11(11), 802–814. https://doi.org/https://doi.org/10.1038/nrm2996
- Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., & Toogood, P. L. (2004). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Molecular Cancer Therapeutics, 3(11), 1427–1438.
- Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., Del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., Neubauer, B. L., Young, J., Chan, E. M., Iversen, P., Cronier, D., Kreklau, E., & de Dios, A. (2014). Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investigational New Drugs, 32(5), 825–837. https://doi.org/https://doi.org/10.1007/s10637-014-0120-7
- Hess, B., Kutzner, C., David, V. D. S., & Lindahl, E. (2008). Gromacs 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation, 4(3), 435–447. https://doi.org/https://doi.org/10.1021/ct700301q
- Kang, Y., Hu, W., Ivan, C., Dalton, H. J., Miyake, T., Pecot, C. V., Zand, B., Liu, T., Huang, J., Jennings, N. B., Rupaimoole, R., Taylor, M., Pradeep, S., Wu, S. Y., Lu, C., Wen, Y., Huang, J., Liu, J., & Sood, A. K. (2013). Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. JNCI: Journal of the National Cancer Institute, 105(19), 1485–1495. https://doi.org/https://doi.org/10.1093/jnci/djt210
- Katsumi, Y., Iehara, T., Miyachi, M., Yagyu, S., Tsubai-Shimizu, S., Kikuchi, K., Tamura, S., Kuwahara, Y., Tsuchiya, K., Kuroda, H., Sugimoto, T., Houghton, P., & Hosoi, H. (2011). Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression. Biochemical and Biophysical Research Communications, 413(1), 62–68. https://doi.org/https://doi.org/10.1016/j.bbrc.2011.08.047
- Kheder, N. A. (2016). Hydrazonoyl chlorides as precursors for synthesis of novel bis-pyrrole derivatives. Molecules (Basel, Switzerland), 21(3), 326. https://doi.org/https://doi.org/10.3390/molecules21030326
- Ku, B. M., Yi, S. Y., Koh, J., Bae, Y. H., Sun, J., Le, e S. H., Ahn, J. S., Park, K., & Ahn, M. J. (2016). The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget, 7(12), 14803–14813. https://doi.org/https://doi.org/10.18632/oncotarget.7543
- Kwapisz, D. (2017). Cyclin-dependent kinase 4/6 inhibitors in breast cancer: Palbociclib, ribociclib, and abemaciclib. Breast Cancer Research and Treatment, 166(1), 41–54. https://doi.org/https://doi.org/10.1007/s10549-017-4385-3
- Lietha, D., & Eck, M. J. (2008). Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One, 3(11), e3800. https://doi.org/https://doi.org/10.1371/journal.pone.0003800
- Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., Kim, S., Parasuraman, S., Caponigro, G., Schnepp, R. W., Wood, A. C., Pawel, B., Cole, K. A., & Maris, J. M. (2013). Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clinical Cancer Research, 19(22), 6173–6182. https://doi.org/https://doi.org/10.1158/1078-0432.CCR-13-1675
- Sánchez-Martínez, C., Gelbert, L. M., Lallena, M. J., & de Dios, A. (2015). DiosCyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorganic & Medicinal Chemistry Letters, 25(17), 3420–3435. https://doi.org/https://doi.org/10.1016/j.bmcl.2015.05.100
- Schaller, M. D. (2010). Cellular functions of FAK kinases: Insight into molecular mechanisms and novel functions. Journal of Cell Science, 123(Pt 7), 1007–1013. https://doi.org/https://doi.org/10.1242/jcs.045112
- Schüttelkopf, A. W., & van Aalten, D. M. F. V. (2004). PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica. Section D, Biological Crystallography, 60(Pt 8), 1355–1363. https://doi.org/https://doi.org/10.1107/S0907444904011679
- Schwartz, M. A., & Ginsberg, M. H. (2002). Networks and crosstalk: Integrin signalling spreads. Nature Cell Biology, 4(4), E65–68. https://doi.org/https://doi.org/10.1038/ncb0402-e65
- Stocker, U., & Gunsteren, W. F. (2000). Molecular dynamics simulation of hen egg white lysozyme: A test of the gromos96 force field against nuclear magnetic resonance data. Proteins: Structure, Function, and Genetics, 40(1), 145–153. https://doi.org/https://doi.org/10.1002/(SICI)1097-0134(20000701)40:1<145::AID-PROT160>3.0.CO;2-Y
- Tanjoni, I., Walsh, C., Uryu, S., Tomar, A., Nam, J., Mielgo, A., Lim, S., Liang, C., Koenig, M., Sun, C., Patel, N., Kwok, C., McMahon, G., Stupack, D. G., & Schlaepfer, D. D. (2010). PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biology & Therapy, 9(10), 764–777. https://doi.org/https://doi.org/10.4161/cbt.9.10.11434
- VanArsdale, T., Boshoff, C., Arndt, K. T., & Abraham, R. T. (2015). Molecular pathways: Targeting the cyclin D-CDK4/6 axis for cancer treatment. Clinical Cancer Research, 21(13), 2905–2910. https://doi.org/https://doi.org/10.1158/1078-0432.CCR-14-0816
- Wang, C., Chang, S., & Gong, X. (2012). Progress in the scoring functions of protein-protein docking. Acta Physico-Chimica Sinica, 28, 751–758.
- Yadav, V., Burke, T. F., Huber, L., Van, H. R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S. B. (2014). The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation. Molecular Cancer Therapeutics, 13(10), 2253–2263. https://doi.org/https://doi.org/10.1158/1535-7163.MCT-14-0257
- Yang, Z. R., & Chou, K. C. (2004). Bio-support vector machines for computational proteomics. Bioinformatics (Oxford, England), 20(5), 735–741. https://doi.org/https://doi.org/10.1093/bioinformatics/btg477
- Zhang, C., Stockwell, S. R., Elbanna, M., Ketteler, R., Freeman, J., Al-Lazikani, B., Eccles, S., De Haven Brandon, A., Raynaud, F., Hayes, A., Clarke, P. A., Workman, P., & Mittnacht, S. (2019). Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene, 38(30), 5905–5920. https://doi.org/https://doi.org/10.1038/s41388-019-0850-2